Acute migraine headache. Migraine
Conditions
Interventions
Intervention 1: Ketorolac 30 mg intravenous. Intervention 2: Metoclopramide 20 mg intravenous. Intervention 3: Biperidine 5 mg intravenous for prevention of metoclopramide side effects. Intervention 4
Treatment - Drugs
Prevention
Placebo
Ketorolac 30 mg intravenous.
Metoclopramide 20 mg intravenous.
Biperidine 5 mg intravenous for prevention of metoclopramide side effects.
Aquapura 5 cc as placebo of biperidine.
Sponsors
Student research committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age older than 15 and younger than 70 years; History of migraine headache with or without aura. Exclusion criteria: Age younger than 15 or older than 70 years; Duration of headache less than 4 or over 72 hours; Patients who had undergone lumbar puncturation(LP) since last 48 hours; Patients who had a systemic headache; Body temperature more than 38 degrees of Celsius; Neurologic deficit; Allergy or tolerance to drugs of study; Participated in other study; Pregnant women; If the patient within 12 hours before entering to the center, received analgesic drug; Patients who for any reason are used analgesics on a daily basis; Patients who can not communicate verbally; If the patient's lost the consciousness due to alcohol consumption and or other material is gone; People with stomach ulcers and severe digestive problems (especially chronic diarrhea); Renal failure; Liver failure; Patients who suffer simultaneously from headaches other than migraine such as tension headaches or sinusitis; If the patient is receiving anticoagulant (due to drug interactions with ketorolac); If the patient is taking probenecid (due to increasing half-life of ketorolac); If the patient receiving phenothiazines, lithium or anti epileptic drugs (due to drug interactions with metoclopramide ); If the patient prior to entering the study have akathisia.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of headache. Timepoint: A moment before the injection, 30 minutes, 60 minutes, 2 hours, 4 hours and 24 hours after the injection. Method of measurement: Visual analoge scale.;24 hours following up. Timepoint: 24 hours after the injection. Method of measurement: After 24 hours, patients are called and asked them to say the severity of their headache as this follow; severe, moderate, mild headache and without headache. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of vertigo( as a side effect of study medication). Timepoint: A moment before injection, 1 hours and 2 hours after injection. Method of measurement: Without vertigo, Mild to moderate vertigo but able to do activities, Sever vertigo and inability to do activities. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArslan Tahmasbi
Ahvaz Jundishapur University of Medical Sciences.
Outcome results
None listed